氟伐他汀对充血性心力衰竭患者血清sICAM-1和sVCAM-1的影响

目的:探讨氟伐他汀短期治疗对充血性心力衰竭(CHF)患者血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和肿瘤坏死因子α(TNF-α)水平的影响。方法:将97例CHF患者随机分为对照组(常规治疗组)和试药组(氟伐他汀组)。采用ELISA测定治疗前及治疗两周后血清中sICAM-1、sVCAM-1和TNF-α水平。结果:两种方法都可以明显降低血清sICAM-1、sVCAM-1和TNF-α水平(P0.05);试药组血清TNF-α水平降低更为显著(P0.05),但血清sICAM-1和sVCAM-1降低水平与对照组无显著差别。结论:在常规治疗基础上短期加用氟伐他汀治疗不能进一步降低CHF患者血清sICAM-1和sVCAM-1水平。     

大剂量氟伐他汀短期治疗对老年不稳定性心绞痛患者血清可溶性细胞黏附分子和肿瘤坏死因子-α水平的影响

目的探讨大剂量氟伐他汀短期治疗对老年不稳定性心绞痛患者血清中可溶性细胞间黏附分子-1（sICAM-1）、可溶性血管细胞黏附分子-1（sVCAM-1）和肿瘤坏死因子-α（TNF-α）水平的影响。方法将56例老年不稳定性心绞痛患者随机分为常规治疗组和大剂量治疗组,两组患者均给予抗心绞痛常规治疗,常规治疗组给予氟伐他汀40mg／d,大剂量治疗组给予氟伐他汀80mg／d,入院当日和治疗1个月时检测患者血清中sICAM-1、sVCAM-1和TNF-α水平。结果两组患者治疗后血清sICAM-1、sVCAM-1和TNF-α水平均较治疗前明显降低（P〈0．05）,但组间比较差异无统计学意义（P〉0．05）。结论大剂量氟伐他汀短期治疗不能进一步降低老年不稳定性心绞痛患者血清sICAM-1、sVCAM-1和TNF-α水平。     

老年ACS患者血浆sICAM-1和sE-selectin的表达及阿托伐他汀对其影响

目的探讨老年急性冠脉综合征（ACS）患者血浆可溶性细胞间黏附分子-1（sICAM-1）和可溶性E-选择素（sE-selectin）的表达及阿托伐他汀对其影响。方法用ELISA法测定90例ACS患者和40例稳定性心绞痛（SAP）患者血浆sICAM-1和sE-selectin水平。同时将ACS患者随机分为高脂血症常规治疗组（A组）、高脂血症阿托伐他汀治疗组（B组）、非高脂血症常规治疗组（C组）、非高脂血症阿托伐他汀治疗组（D组）;B、D组在常规治疗的基础上每日口服10 mg阿托伐他汀,共8周。检测各组治疗前后血浆sICAM-1和sE-selectin水平变化。结果ACS组sICAM-1和sE-selectin水平均高于SAP组（P〈0.05,〈0.01）;阿托伐他汀治疗后,B、D组sICAM-1和sE-se-lectin水平较治疗前降低。结论血浆sICAM-1和sE-selectin水平与不同类型冠心病斑块稳定性有关,阿托伐他汀具有抑制细胞黏附分子表达,稳定动脉粥样硬化斑块的作用。     

阿托伐他汀对ACS患者介入治疗后hs-CRP、slCAM-1及sVCAM-1的影响

目的:观察不同剂量的阿托伐他汀对急性冠状动脉综合征(ACS)患者冠状动脉介入(PCI)围手术期的炎性因子及血清黏附因子的影响。方法:将入选的120例ACS患者,随机分为治疗组和对照组,每组60例,治疗组给予阿托伐他汀40mg/d,对照组给予阿托伐他汀20mg/d。于PCI术前、术后1周及2周测血浆高敏C反应蛋白(hs-CRP)、血浆可溶性细胞间黏附分子(sICAM-1)及血管细胞黏附分子(sVCAM-1)。结果:治疗组在PCI术后1周和2周,hs-CRP、sICAM-1和sVCAM-1显著低于对照组(P0.01)。结论:较大剂量阿托伐他汀能够抑制PCI术后炎症反应,显著降低slCAM-1和sVCAM-1水平。     

ACS患者血清sICAM-1、sVCAM-1、可溶性P选择素的水平变化及意义

目的探讨血清可溶性细胞间黏附分子1（sICAM-1）、可溶性血管细胞间黏附分子1（sVCAM-1）、可溶性P选择素（sP选择素）在急性冠脉综合征（ACS）发生、发展中的作用。方法采用ELISA法测定50例ACS患者（ACS组）、40例稳定型心绞痛（SAP）患者（SAP组）及26例正常人（对照组）sICAM-1、sVCAM-1、sP选择素水平。结果ACS组血清sICAM-1、sVCAM-1、sP选择素水平显著高于SAP组和对照组（P均〈0．01）。ACS组血清sICAM-1、sVCAM-1与sP选择素呈显著正相关（r=0．432、0．501,P均〈0．05）。结论ACS患者血清sICAM-1、sVCAM-1和sP选择素共同作用促进ACS的发生、发展。     

急性冠状动脉综合征患者血清sICAM-1、sVCAM-1、sP-选择素表达及意义

采用ELISA法测定40例急性冠脉综合征患者（AC组）、30例稳定型心绞痛患者（SAP组）及28例正常人（对照组）血清可溶性细胞间黏附分子-1（sICAM-1）、血管细胞间黏附分子-1（sVCAM-1）、P-选择素（sP-selectin）水平。结果ACS组血清sICAM-1、sVCAM-1、sP-selectin水平显著高于SAP组和对照组（P均〈0.01）,SAP组与对照组无显著性差异（P〉0.05）。ACS组血清sICAM-1、sVCAM-1与sP-selectin呈显著正相关（r=0.516、0.521,P均〈0.05）。提示ACS患者血清sICAM-1、sVCAM-1、sP-selectin水平均明显升高,并共同作用促进ACS的发生、发展。     

氟伐他汀对冠心病患者血脂及细胞黏附分子表达的影响

对76例冠心病高脂血症患者在常规治疗的基础上口服氟伐他汀胶囊40 m g/d,1周后20 m g/d,连用6~8周,观察治疗前后血脂及血清可溶性细胞间黏附分子-1(sICAM-1)和血管细胞黏附分子-1(sVCAM-1)变化。结果治疗后TG、TC、LDLC明显降低,HDLC明显升高;sICAM-1和sVCAM-1表达明显降低。认为氟伐他汀除可调整血脂外,还具有抗动脉粥样硬化的作用,可用于冠心病的预防和治疗。     

氟伐他汀对心力衰竭患者血清可溶性细胞黏附分子的影响

目的:观察氟伐他汀短期治疗对充血性心力衰竭(congestive heart failure,CHF)患者血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性选择素E(sE- selectin)、可溶性选择素P(sP- selectin)和可溶性选择素L(sL- selectin)水平的影响,探讨氟伐他汀对CHF的治疗作用.方法:将70例CHF患者随机分为常规治疗组和干预组(氟伐他汀组).正常对照组20例.采用酶联免疫吸附法(ELISA)测定其治疗前后血清中sICAM-1、sVCAM-1、sE- selectin、sP- selectin和sL- selectin水平.结果:血清可溶性细胞黏附分子(soluble cell adhesion molecules ,sCAM)水平在心功能Ⅳ级明显高于心功能Ⅱ、Ⅲ级患者,而心功能Ⅱ、Ⅲ级之间比较差异无统计学意义,心功能Ⅱ-Ⅳ级的患者sCAM水平均高于正常对照组(P<0.05或P<0.01).常规治疗组和干预组治疗后血清sCAM水平均较治疗前有显著下降(P<0.05或P<0.01),但干预组较常规治疗组仅sVCAM-1和sE- selectin下降水平显著(P<0.05),余各血清sCAM水平组间比较差异无统计学意义(P>0.05).结论:CHF患者血清sCAM水平下降主要与心功能改善相关,在CHF常规治疗的基础上短期加用氟伐他汀治疗能降低sVCAM-1和sE-selectin水平.     

有氧运动对急性冠脉综合征患者血清黏附分子和C反应蛋白的影响

目的: 探讨有氧运动对急性冠脉综合征(ACS)患者可溶性细胞间黏附分子-1(sICAM-1)、血管细胞黏附分子-1(sVCAM-1)和C反应蛋白(CRP)水平的影响。方法: 选取ACS患者70例,将其分为常规治疗组和有氧运动+常规治疗组（加有氧运动组）。另选健康成人为正常对照组。采用酶联免疫吸附法测定各组sICAM-1和sVCAM-1 水平,采用免疫浊度法测定CRP浓度。结果: ACS 患者循环血中sICAM-1、sVCAM-1和CRP水平明显高于正常对照组(P<0.01),两组治疗1个月后sICAM-1、sVCAM-1和CRP水平均较治疗前均明显下降(P<0.05和P<0.01)。且两组各项指标比较,加有氧运动组降低更显著(P<0.05)。结论: ACS 患者血清中sICAM-1、sVCAM-1和CRP水平明显升高,而有氧运动能明显降低ACS患者血中sICAM-1、sVCAM-1和CRP水平。     

瑞舒伐他汀对老年原发性高血压患者超敏C反应蛋白和细胞间黏附分子-1的影响

目的 探讨瑞舒伐他汀对老年原发性高血压患者超敏C反应蛋白(hs-CRP)和细胞间黏附分子-1(ICAM-1)的影响.方法 将44例患者随机分为常规治疗组和瑞舒伐他汀组.常规组采用氨氯地平治疗,如血压未达标则加用缬沙坦和比索洛尔至血压达标.治疗组在常规组治疗基础上加用瑞舒伐他汀片10 mg/d,连用4周.治疗前、后采用双抗体夹心ABC-ELISA法检测血清hs-CRP和ICAM-1浓度并进行统计学比较.结果 与治疗前相比,两组治疗后4周血清hs-CRP和ICAM-1水平显著下降,差异有统计学意义(P＜0.01).治疗后4周,瑞舒伐他汀组的血清hs-CRP和ICAM-1水平比常规治疗组下降更多,差异有统计学意义(分别为t=2.1267,P=-0.0333; t=5.7905,P=-0.0000).结论 瑞舒伐他汀等他汀类药物可降低老年原发性高血压患者血清hs-CRP和ICAM-1等促炎性细胞因子的水平,减轻高血压患者的血管内炎症.     

调脂治疗对急性脑梗死患者血清炎性因子水平的影响

目的探讨阿托伐他汀调脂治疗对急性脑梗死患者血清炎性因子水平的影响。方法选择急性脑梗死患者120例,根据颈动脉超声检查结果分为稳定斑块组60例和易损斑块组60例,2组又随机各选30例分别服用阿托伐他汀10mg/晚(小剂量)和阿托伐他汀40 mg/晚(大剂量)治疗。所有患者治疗前和治疗后2周,检测血脂及血清高敏C反应蛋白(hs-CRP)、可溶性细胞间黏附因子1(sICAM-1)、可溶性血管细胞黏附分子1(sVCAM-1)和可溶性CD40配体(sCD40L)及基质金属蛋白酶3(MMP-3)。结果治疗前,易损斑块组sCD40L、sVCAM-1和MMP-3水平明显高于稳定斑块组(P<0.05,P<0.01)。治疗后2周,2组大剂量治疗患者血清LDL-C、hs-CRP、sICAM-1、sVCAM-1、sCD40L和MMP-3水平明显低于小剂量治疗患者(P<0.01)。结论大剂量阿托伐他汀调脂治疗,能降低患者血清炎性因子的水平,具有抑制炎症和稳定斑块作用。     

Influence of hepatitis C virus infection on soluble cellular adhesion molecules in hemodialysis patients

BACKGROUND/AIMS: Higher levels of soluble cellular adhesion molecules have been found to be a strong indicator of endothelial dysfunction and atherosclerosis in the general population. In hemodialysis patients, soluble cellular adhesion molecules have been found at higher levels as well. Such an increase has been considered as a sign of chronic inflammation. Chronic viral hepatitis C (HCV) infection, highly prevalent in hemodialysis patients, is also a disease that can induce chronic inflammation. We conducted a cross-sectional association study of soluble cellular adhesion molecules and hepatitis C in maintenance hemodialysis patients. METHODS: A total of 87 stable hemodialysis patients were included in this study, mean age was 60.0 +/- 13.7 years. Anti-HCV antibody and HCV RNA assay were done. Patients were divided into anti-HCV-positive and anti-HCV-negative groups. Predialytic serum soluble intercellular adhesion molecules-1 (sICAM-1), soluble vascular cellular adhesion molecules-1 (sVCAM-1), and soluble E-selectin were assayed by commercially available enzyme-linked immunosorbent assay (ELISA) kits. The results were correlated with other hematological and biochemical results. RESULTS: In the anti-HCV-positive group, the time on hemodialysis was longer (105.5 +/- 65.7 vs. 49.2 +/- 44.0 months, p = 0.001). The sICAM-1, sVCAM-1 and E-selectin levels were higher in the anti-HCV-positive group. HCV infection was determined as an independent determinant of sICAM-1 and sVCAM-1 by multiple linear regression analysis. CONCLUSION: Elevated serum soluble cellular adhesion molecules are multifactorial in hemodialysis patients. The role of HCV infection must be considered. The clinical significance and implications of soluble cellular adhesion molecules remains to be elucidated.     

Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy

In chronic hepatitis C (CHC) intercellular and vascular cell adhesion molecules-1 (ICAM-1 and VCAM-1) are expressed de novo on hepatocytes infected by hepatitis C virus and on endothelial cells from sinusoidal vessels, respectively. The soluble forms of these (sICAM-1 and sVCAM-1) reflect their level of expression in tissue. Serum levels of sICAM-1 and VCAM-1 were measured using ELISA assays in 20 patients with CHC, at baseline and after 6 months of treatment with interferon-a + ribavirin. Significantly higher mean values of both adhesions, comparing to healthy controls, were observed. In all patients the lowest value of sICAM-1 was above highest level of controls. At the beginning of the study the responders and nonresponders to treatment (at 1 year) did not differ from each others concerning sICAM-1/sVCAM-1 concentrations. A significant reduction of sICAM-1 levels was apparent after 6 months of therapy, especially in the group of responders. Just a normalization of sICAM-1 values in all but one of responders, comparing to only 5 of 9 nonresponders has been achieved. By contrast, the mean level of sVCAM-1 did not change significantly with therapy. In conclusion, the normalization of serum sICAM-1 at 6 months of treatment may be useful prognostic parameter of response to the end of the administration period (1 year).     

胃肿瘤患者循环可溶性细胞间粘附分子-1和血管细胞粘附分子-1

AIM To elucidate the biological and clinical significance of sICAM-1 and sVCAM-1 in patients with gastric cancer.METHODS The serum levels of soluble ICAM-1 and VCAM-1 were measured with sandwith enzyme immunoassay.RESULTS In gastric cancer patients, soluble ICAM-1 and VCAM-1 concentrations were significantly elevated in comparision with those of healthy subjects (289.23μg/L±32.69μg/L vs 190.44μ/L±35.92μg/L,1430.88μg/L±421.71μg/L vs 727.24μg/L±157.68μg/L, respectively, P＜0.01). The increment in serum sICAM-1 and sVCAM-1 concentrations correlated well with the staging of gastric cancer. The serum levels of sICAM-1 and sVCAM-1 in patients of Ⅲ-Ⅳ stages were higher than those of Ⅰ-Ⅱ stages (346.60μg/L±92.10μg/L vs 257.54μg/L±32.77μg/L, 1800.60μg/L±510.76μg/L vs 1262.81μg/L±236.73μg/L). The levels of sICAM-1 and sVCAM-1 were correlated significantly (r=0.49,P＜0.01). The sICAM-1 and sVCAM-1 levels correlated positively with alkaline phophatase (r=0.63,0.71,P＜0.001) and white cell count (r=0.52,0.43, P＜0.01); but correlated negatively with serum albumin (r=-0.41, -0.49, P＜0.01).CONCLUSION The measurement of circulating ICAM-1 and VCAM-1 may bring additional prognostic information for patients with gastric cancer in varying stages.INTRODUCTIONTumor growth and metastasis involves a variety of cell-cell and cell-extracellular matrix interactions mediated by cell adhesion molecules. Currently, a number of cell adhesion molecules, such as intercellular adhesion molecules-1 (ICAM-1), vascular cell adhesion molecules-1 (VCAM-1), etc. have been found.ICAM-1 and VCAM-1 are members of the immunoglobulin supergene family which are cytokine-induced glycoproteins (IL-1, TNFα and IFNγ). Both of them have five or seven extracellular immunoglobulin-like domains, a single transmembranous domain and a short cytoplasmic tail[1,2]. The natural ligand of ICAM-1 or VCAM-1 is LFA-1 (CD11a) and Mac-1 (CD11b) or VLA-4, respectively[3]. ICAM-1 is a widely distributed protein on a variety of tissues, and can be detected in many cells such as macrophage, T- and B-cells, or fibroblasts, endothelial and epithelial cells. VCAM-1 is also a widely distributed protein and is constitutively expressed on tissue macrophage, dentritic cells in lymphoid tissue and skin, as well as on bone marrow fibroblasts and epithelial cells. Expression of VCAM-1 is inducible on vascular endothelial cells under pathological conditions[4].Recently, soluble forms of several adhesion molecules including ICAM-1 and VCAM-1 were found in serum of normal donors[5]. Abnormally high levels of them have been described in some solid malignant tumors, leukemia, autoimmune disease, infectious disease, etc.The present study was carried out to measure the circulating levels of sICAM-1 and sVCAM-1 in gastric cancer before treatment was given and to study their correlation with clinical, histological and routine laboratory parameters.     

Circulating soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in immunocompetent and renal transplant patients: correlation with cytomegalovirus disease and renal function.

The plasma levels of the soluble adhesion molecules, soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1), were measured before and after transplantation in 26 renal transplant recipients, and in 173 longitudinally collected samples in 17 of the patients. The patients were carefully monitored for the presence of cytomegalovirus (CMV) infection and rejection. Forty healthy blood donors and 12 otherwise healthy subjects with symptomatic primary CMV infections served as controls. During CMV disease, plasma levels of sVCAM-1 and sICAM-1 were elevated in both renal transplant patients and otherwise healthy subjects with CMV disease. The sVCAM-1 levels were strongly elevated before transplantation in renal transplant recipients and correlated with creatinine levels. Increased sVCAM-1 levels were also registered during rejection episodes. CMV disease, per se, is associated with markedly increased levels of sVCAM-1 and sICAM-1. There is also a correlation of sVCAM-1 levels with serum creatinine levels. Thus, the presence of CMV infection and renal function are factors that must be considered in further studies of soluble adhesion molecules.     

Relevance of erythrocyte deformability to the concentration of soluble cell adhesion molecules and glomerular filtration rate in patients with untreated essential hypertension

Relationship between erythrocyte deformability and: a) soluble cell adhesion molecules concentration, b) glomerular filtration rate (eGFR) has been investigated in three study groups: a group of 20 patients with diagnosed arterial hypertension, a group of 20 individuals with exclusively hypercholesterolemia and a group of 22 healthy persons. The individuals with hypertension or hypercholesterolemia were free of any other cardiovascular disease risk factor and were not on any therapy prior to entering the study. Clinical and laboratory data included systolic and diastolic blood pressure (obtained by ABPM), lipids profile, eGFR, red blood cell (RBC) deformability (assessed by shear stress laser diffractometry) and levels of circulating soluble vascular adhesion molecules-1 (sVCAM-1) as well as soluble intracellular adhesion molecules-1 (sICAM-1). In the group of hypertensives, RBC deformability and concentration of circulating soluble adhesion molecules showed statistically significant negative correlations: RBC deformability decreases with increasing level of: a) sVCAM-1, R = -0.61, p < 0.002, b) sIVCAM-1, R = -0.53, p < 0.009. In parallel, statistically significant increase of eGFR was observed with rising erythrocyte deformability, R = 0.60, p < 0.005. In the groups of healthy individuals and patients with hypercholesterolemia there was no sign of any correlations between the considered parameters. The observed correlations suggest that in patients diagnosed exclusively with hypertension, firstly, erythrocyte deformability may serve as a marker of endothelial dysfunction and, secondly, red blood cells may be mediators of adverse changes in kidneys.     

Effects of severe,uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor

OBJECTIVES : The molecular mechanisms whereby severe, uncontrolled hypertension (SHT) is translated into acute vascular target organ dysfunction have not been completely defined. We sought to determine whether SHT is associated with pressure-dependent endothelial activation as assessed by soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1) and von Willebrand Factor (vWF). METHODS : We determined sVCAM-1, sICAM-1 and vWF in three groups: (i) untreated patients referred specifically for treatment of SHT [diastolic blood pressure (DBP) > or = 120 mm Hg; n = 24]; (ii) untreated patients with established mild hypertension (MHT; DBP 95-100 mmHg; n = 19); and (iii) normotensive volunteers (DBP < or = 90; n = 16). RESULTS : By analysis of variance, sVCAM-1 (P = 0.002), sICAM-1 (P = 0.02) and vWF (P = 0.009) were greater in SHT and MHT than in normotensives but did not differ between SHT and MHT. We observed a significant positive correlation between blood pressure and soluble activation markers at lower blood pressures (normotensives and MHT considered together) that was not present in SHT. CONCLUSIONS : Even mild elevation of blood pressure may be sufficient to activate the expression of adhesion molecules. Mechanisms other than the endothelial expression of adhesion molecules may be important in mediating the accelerated target organ injury produced by SHT in humans. Concentrations of soluble adhesion molecules and vWF may depend more strongly upon factors in the hypertensive microenvironment other than the absolute level of blood pressure.     

sICAM-1、sVCAM-1在急性动脉硬化性脑梗死中的临床意义

目的:探讨可溶性细胞间黏附分子-1(sICAM-1)及可溶性血管细胞间黏附分子-1(sVCAM-1)在急性动脉硬化性脑梗死中的临床意义。方法:研究对象分为急性脑梗死组(n=60例)及对照组(n=28例),检测所有受试者血清sICAM-1、sVCAM-1水平,分析二者与脑梗死面积及临床转归之间的关系。结果:急性脑梗死患者血清sICAM-1、sVCAM-1水平显著高于对照组(P<0.01),二者与梗死面积大小呈正相关;而不同转归组之间二者含量无显著差别。结论:sICAM-1、sVCAM-1参与脑梗死炎症过程,可预示脑梗死严重程度。